ADRs quickly rose 14% on a report that Halozyme Therapeutics (HALO) has expressed takeover interest. Halozyme has recently ...

Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...

Van ECK Associates Corp reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 35.5% in the 3rd quarter, according to the company in its most recent 13F filing with the ...

Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.

A $1000 investment made in November 2014 would be worth $6,540.57, or a gain of 554.06%, as of November 8, 2024, according to our calculations. This return excludes dividends but includes price ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

Analysts anticipate Halozyme Therapeutics to report an earnings per share (EPS) of $0.98. Investors in Halozyme Therapeutics ...

Halozyme Therapeutics ( (HALO) ) has released its Q3 earnings. Here is a breakdown of the information Halozyme Therapeutics presented to its ...

JMP Securities analyst Jason Butler has reiterated their bullish stance on HALO stock, giving a Buy rating yesterday. Jason Butler has given ...

According to Benzinga Pro, Halozyme Therapeutics's peer group average for short interest as a percentage of float is 10.61%, which means the company has more short interest than most of its peers. Did ...

Verdence Capital Advisors LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% in the third quarter, according to the company in its most recent 13F ...